This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, J. Articles by Sauter, G. Search for Related Content PubMed PubMed Citation Articles by Zhao, J. Articles by Sauter, G.

Chromosomal Imbalances in Noninvasive Papillary Bladder Neoplasms (pTa)¹

Institute of Pathology [J. Z., J. R., U. W., B. R., P. S., H. M., M. J. M., G. S.] and Urologic Clinics [T. C. G.], University of Basel, 4003 Basel, and Institute of Pathology [U. S.] and Urologic Clinics [T. Z., D. A.], Cantonal Hospital St.Gallen, 9007 St. Gallen, Switzerland

Almost 70% of urinary bladder neoplasms present as low-grade papillary noninvasive tumors (stage pTa). To determine which genomic alterations can occur in pTa tumors of different grades and to evaluate the prognostic significance of chromosomal imbalances, we analyzed 113 pTa tumors (40 grade 1, 55 grade 2, 18 grade 3) by comparative genomic hybridization. pTaG1 (1.9 ± 2.0) and pTaG2 (3.1 ± 2.9) tumors had only few genomic alterations with 9q- (44%), 9p- (36%), and -Y (21%) being most prevalent. Neither the total number of aberrations nor any individual alteration was linked to the risk of recurrence in 95 pTaG1/G2 tumors with clinical follow-up information. pTaG3 tumors were characterized by a high number of alterations (7.7 ± 4.5; P < 0.0001 for G3 versus G2). Several chromosomal imbalances that have previously been reported to be typical for invasive bladder neoplasms were significantly more frequent in pTaG3 than in pTaG2 tumors, including 2q-, 5p+, 5q-, 6q-, 8p-, 10q-, 18q-, and 20q+. A malfunction of genes at these loci may contribute to the development of high-grade urothelial neoplasias. However, there is no evidence for a direct role of these alterations for development of invasive tumor growth.

This article has been cited by other articles:

				M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]

				E. Blaveri, J. L. Brewer, R. Roydasgupta, J. Fridlyand, S. DeVries, T. Koppie, S. Pejavar, K. Mehta, P. Carroll, J. P. Simko, et al. Bladder Cancer Stage and Outcome by Array-Based Comparative Genomic Hybridization Clin. Cancer Res., October 1, 2005; 11(19): 7012 - 7022. [Abstract] [Full Text] [PDF]

				R. Natrajan, J. Louhelainen, S. Williams, J. Laye, and M. A. Knowles High-Resolution Deletion Mapping of 15q13.2-q21.1 in Transitional Cell Carcinoma of the Bladder Cancer Res., November 15, 2003; 63(22): 7657 - 7662. [Abstract] [Full Text] [PDF]

				B. W.G. van Rhijn, A. N. Vis, T. H. van der Kwast, W. J. Kirkels, F. Radvanyi, E. C.M. Ooms, D. K. Chopin, E. R. Boeve, A. C. Jobsis, and E. C. Zwarthoff Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome J. Clin. Oncol., May 15, 2003; 21(10): 1912 - 1921. [Abstract] [Full Text] [PDF]

				J. Cheng, H. Huang, J. Pak, E. Shapiro, T.-T. Sun, C. Cordon-Cardo, F. M. Waldman, and X.-R. Wu Allelic Loss of p53 Gene Is Associated with Genesis and Maintenance, but not Invasion, of Mouse Carcinoma in Situ of the Bladder Cancer Res., January 1, 2003; 63(1): 179 - 185. [Abstract] [Full Text] [PDF]

				L. E. Moore, A. H. Smith, C. Eng, D. Kalman, S. DeVries, V. Bhargava, K. Chew, D. Moore II, C. Ferreccio, O. A. Rey, et al. Arsenic-Related Chromosomal Alterations in Bladder Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1688 - 1696. [Abstract] [Full Text] [PDF]

				J. F. Schmitt, D. S. Millar, J. S. Pedersen, S. L. Clark, D. J. Venter, M. Frydenberg, P. L. Molloy, and G. P. Risbridger Hypermethylation of the Inhibin {alpha}-Subunit Gene in Prostate Carcinoma Mol. Endocrinol., February 1, 2002; 16(2): 213 - 220. [Abstract] [Full Text] [PDF]

				M A Knowles What we could do now: molecular pathology of bladder cancer Mol. Pathol., August 1, 2001; 54(4): 215 - 221. [Abstract] [Full Text] [PDF]

				R. Simon, J. Richter, U. Wagner, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, et al. High-Throughput Tissue Microarray Analysis of 3p25 (RAF1) and 8p12 (FGFR1) Copy Number Alterations in Urinary Bladder Cancer Cancer Res., June 1, 2001; 61(11): 4514 - 4519. [Abstract] [Full Text] [PDF]

				R. Simon, E. Eltze, K.-L. Schäfer, H. Bürger, A. Semjonow, L. Hertle, B. Dockhorn-Dworniczak, H.-J. Terpe, and W. Böcker Cytogenetic Analysis of Multifocal Bladder Cancer Supports a Monoclonal Origin and Intraepithelial Spread of Tumor Cells Cancer Res., January 1, 2001; 61(1): 355 - 362. [Abstract] [Full Text]

				J. Zhao, R. R. de Krijger, D. Meier, E.-J. M. Speel, P. Saremaslani, S. Muletta-Feurer, C. Matter, J. Roth, P. U. Heitz, and P. Komminoth Genomic Alterations in Well-Differentiated Gastrointestinal and Bronchial Neuroendocrine Tumors (Carcinoids) : Marked Differences Indicating Diversity in Molecular Pathogenesis Am. J. Pathol., November 1, 2000; 157(5): 1431 - 1438. [Abstract] [Full Text] [PDF]

				J. Richter, U. Wagner, J. Kononen, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, et al. High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer Am. J. Pathol., September 1, 2000; 157(3): 787 - 794. [Abstract] [Full Text] [PDF]

				I. A. Sokolova, K. C. Halling, R. B. Jenkins, H. M. Burkhardt, R. G. Meyer, S. A. Seelig, and W. King The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine J. Mol. Diagn., August 1, 2000; 2(3): 116 - 123. [Abstract] [Full Text]